contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


toleranzia-submits-a-clinical-trial-application-cta-for-the-drug-candidate-tol2-for-the-treatment-of-myasthenia-gravis

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Toleranzia is a research company focused on the development of drug candidates for the treatment of autoimmune diseases. The company has developed a platform technology focused on the muscular disease myasthenia gravis. In addition, the technology has been used in other areas such as diabetes and multiple sclerosis. Research collaboration is done together with external partners within the field. The head office is based in Gothenburg.

Toleranzia

Toleranzia AB (the ”Company" or "Toleranzia") today announces that it has filed a CTA with the European Medicines Agency (EMA) for a Phase I/IIa trial with the Company´s drug candidate TOL2 ...

<div class="mfn-preamble">Toleranzia AB (the ”Company" or "Toleranzia") today announces that it has filed a CTA with the European Medicines Agency (EMA) for a Phase I/IIa trial with the Company´s drug candidate TOL2 in patients with the autoimmune disease myasthenia gravis.</div><div class="mfn-body">The trial will be a multi-center, placebo-controlled, first in human (FiH) study in myasthenia gravis patients receiving one or more doses of increasing amounts of TOL2 (in the so-called single and multiple ascending dose parts of the study) to evaluate the safety, tolerability and preliminary efficacy of TOL2. Clinical centers in Sweden, Denmark and Germany will participate in the trial, which will be managed by Toleranzia’s partner Clinical Trial Consultants (CTC). &nbsp; Large-scale manufacturing of lyophilized TOL2 drug product for the trial is currently ongoing at Curia Global in Scotland, and labelling, storing and distribution of the drug to participating clinics will be managed by Toleranzia’s partner ClinStorage AB. &nbsp; "With this clinical trial application for TOL2, Toleranzia reaches its most important milestone to date, and I am very grateful for all the hard work that our employees and partners have put in to achieve this. Following regulatory approval, we are ready and eager to start the clinical trial as soon as possible in patients with myasthenia gravis, a patient group that is in great need of safer and more effective treatments”, comments Charlotte Fribert, CEO, Toleranzia. &nbsp; For further information, please contact Charlotte Fribert - CEO, Toleranzia AB Tel: +46 763 19 98 98 Email: <a rel="noopener" href="mailto:charlotte.fribert@toleranzia.com">charlotte.fribert@toleranzia.com</a> &nbsp; About Toleranzia AB (publ) Toleranzia AB (publ) develops medicines that harness the power of the immune system to treat rare autoimmune diseases. The drugs, which target the cause of the disease, can cure or significantly alleviate the disease and not, like current treatments, just reduce symptoms. They have the potential to be the first long-acting or curative treatments that act specifically on the underlying cause of the autoimmune orphan disease for which they are being developed. Toleranzia's shares are listed on Nasdaq First North Growth Market and Mangold Fondkommission AB, 08-503 015 50, CA@mangold.se, is the company's Certified Adviser.</div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments<hr><a rel="noopener" href="https://storage.mfn.se/9c36022c-7e43-4d55-86a6-6b814454386f/toleranzia-submits-a-clinical-trial-application-cta-for-the-drug-candidate-tol2-for-the-treatment-of-myasthenia-gravis.pdf" class="mfn-generated mfn-primary">Toleranzia submits a clinical trial application (CTA) for the drug candidate TOL2 for the treatment of myasthenia gravis</a></div>

Toleranzia submits a clinical trial application (CTA) for the drug candidate TOL2 for the treatment of myasthenia gravis

Probabilities of success in drug development

Return on capital (ROE, ROI, ROIC, RONIC)

Drug development investment: Value creation through M&As and licensing agreements

Valuation methods: Valuation multiples

Helsinki Stock Exchange is cheap

Tilmeld dig vores nyhedsbrev - ingen konto nødvendig!